Other languages Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Delayed Nasdaq Other stock markets 12:29:21 2024-06-03 pm EDT			5-day change	1st Jan Change
0.539 ^USD	+1.51%		+21.45%	+18.46%

May. 13	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	May. 22
Shuttle Pharma Provides First Quarter 2024 Corporate Update	May. 14
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	Apr. 23
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024	Apr. 03
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	Mar. 25
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	Mar. 22
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024	Mar. 05
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering	Feb. 13
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	Feb. 06
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	Jan. 23
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	Jan. 08
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	Dec. 12
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	Dec. 11
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023	Nov. 30
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update	Nov. 14
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program through Exclusive License Agreement	Nov. 01
Shuttle Pharmaceuticals : Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement - Form 8-K	23-10-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Other languages

Filters